Trial Profile
A study evaluating effect of immunization campaign using the 4-component protein-based meningococcal vaccine (MenB-4C) in Saguenay-Lac-Saint-Jean (SLSJ) region.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Oct 2017
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group B (Primary)
- Indications Meningococcal group B infections
- Focus Therapeutic Use
- 09 Oct 2017 New trial record